|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Inaba H, Greaves M and Mullighan CG: Acute
lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013. View Article : Google Scholar
|
|
3
|
Greaves M: Infection, immune responses and
the aetiology of childhood leukaemia. Nat Rev Cancer. 6:193–203.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sherborne AL, Hosking FJ, Prasad RB, et
al: Variation in CDKN2A at 9p21.3 influences childhood acute
lymphoblastic leukemia risk. Nat Genet. 42:492–494. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vijayakrishnan J and Houlston RS:
Candidate gene association studies and risk of childhood acute
lymphoblastic leukemia: a systematic review and meta-analysis.
Haematologica. 95:1405–1414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Y, Chen J, Li J, et al: Association
of three polymorphisms in ARID5B, IKZF1 and CEBPE with the risk of
childhood acute lymphoblastic leukemia in a Chinese population.
Gene. 524:203–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Speedy HE, Di Bernardo MC, Sava GP, et al:
A genome-wide association study identifies multiple susceptibility
loci for chronic lymphocytic leukemia. Nat Genet. 46:56–60. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schinkel AH: The physiological function of
drug-transporting P-glycoproteins. Semin Cancer Biol. 8:161–170.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin JH and Yamazaki M: Role of
P-glycoprotein in pharmacokinetics: clinical implications. Clin
Pharmacokinet. 42:59–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hodges LM, Markova SM, Chinn LW, Gow JM,
Kroetz DL, Klein TE and Altman RB: Very important pharmacogene
summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics.
21:152–161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Breier A, Barancík M, Sulová Z and Uhrík
B: P-glycoprotein - implications of metabolism of neoplastic cells
and cancer therapy. Curr Cancer Drug Targets. 5:457–468. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoffmeyer S, Burk O, von Richter O, et al:
Functional polymorphisms of the human multidrug-resistance gene:
multiple sequence variations and correlation of one allele with
P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci
USA. 97:3473–3478. 2000. View Article : Google Scholar
|
|
13
|
Kurata Y, Ieiri I, Kimura M, et al: Role
of human MDR1 gene polymorphism in bioavailability and interaction
of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther.
72:209–219. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lamba J, Strom S, Venkataramanan R, et al:
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal
and induction phenotype. Clin Pharmacol Ther. 79:325–338. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jamroziak K, Balcerczak E, Smolewski P, et
al: MDR1 (ABCB1) gene polymorphism C3435T is associated with
P-glycoprotein activity in B-cell chronic lymphocytic leukemia.
Pharmacol Rep. 58:720–728. 2006.PubMed/NCBI
|
|
16
|
Hattori H, Suminoe A, Wada M, et al:
Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are
associated with the development of childhood acute lymphoblastic
leukemia. Leuk Res. 31:1633–1640. 2007. View Article : Google Scholar
|
|
17
|
Rao DN, Anuradha C, Vishnupriya S, Sailaja
K, Surekha D, Raghunadharao D and Rajappa S: Association of an MDR1
gene (C3435T) polymorphism with acute leukemia in India. Asian Pac
J Cancer Prev. 11:1063–1066. 2010.PubMed/NCBI
|
|
18
|
Marzolini C, Paus E, Buclin T and Kim RB:
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and
clinical relevance. Clin Pharmacol Ther. 75:13–33. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Robert J, Morvan VL, Smith D, Pourquier P
and Bonnet J: Predicting drug response and toxicity based on gene
polymorphisms. Crit Rev Oncol Hematol. 54:171–196. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brambila-Tapia AJ: MDR1 (ABCB1)
polymorphisms: functional effects and clinical implications. Rev
Invest Clin. 65:445–454. 2013.PubMed/NCBI
|
|
21
|
Urayama KY, Wiencke JK, Buffler PA,
Chokkalingam AP, Metayer C and Wiemels JL: MDR1 gene variants,
indoor insecticide exposure, and the risk of childhood acute
lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev.
16:1172–1177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu RR: The role of multidrug resistance
gene 1 polymorphism to prognosis of adult acute lymphoblastic
leukemia patients. Central South University. 5:1–48. 2008.(In
Chinese).
|
|
23
|
Gréen H, Falk IJ, Lotfi K, et al:
Association of ABCB1 polymorphisms with survival and in vitro
cytotoxicty in de novo acute myeloid leukemia with normal
karyotype. Pharmacogenomics J. 12:111–118. 2012.PubMed/NCBI
|
|
24
|
Lü H, Du ZZ, Wang W, et al: Relationship
between genetic polymorphism of multidrug resistance 1 gene and the
risk of childhood acute lymphocytic leukemia. Zhonghua Er Ke Za
Zhi. 50:692–696. 2012.(In Chinese).
|
|
25
|
Singh O, Chan JY, Lin K, Heng CC and
Chowbay B: SLC22A1-ABCB1 haplotype profiles predict imatinib
pharmacokinetics in Asian patients with chronic myeloid leukemia.
PLoS One. 7:e517712012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vivona D, Bueno CT, Lima LT, et al: ABCB1
haplotype is associated with major molecular response in chronic
myeloid leukemia patients treated with standard-dose of imatinib.
Blood Cells Mol Dis. 48:132–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhai X, Wang H, Zhu X, et al: Gene
polymorphisms of ABC transporters are associated with clinical
outcomes in children with acute lymphoblastic leukemia. Arch Med
Sci. 8:659–671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elghannam DM, Ibrahim L, Ebrahim MA, Azmy
E and Hakem H: Association of MDR1 gene polymorphism (G2677T) with
imatinib response in Egyptian chronic myeloid leukemia patients.
Hematology. 19:123–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sai K, Kaniwa N, Itoda M, Saito Y,
Hasegawa R, Komamura K, et al: Haplotype analysis of ABCB1/MDR1
blocks in a Japanese population reveals genotype-dependent renal
clearance of irinotecan. Pharmacogenetic. 13:741–757. 2003.
View Article : Google Scholar
|
|
30
|
Semsei AF, Erdélyi DJ, Ungvári I, et al:
Association of some rare haplotypes and genotype combinations in
the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk
Res. 32:1214–1220. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin JY, Huang Q, Yang Y, Zhang JT, Zhong
MZ, Zhou HH and Liu ZQ: Characterization and analyses of multidrug
resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in
Chinese population. Pharmacogenet Genomics. 19:206–216. 2009.
View Article : Google Scholar
|
|
32
|
Qian X, Cao S, Yang G, Dong J, Jin G, Shen
Y and Hu Z: Variant genotypes of MDR1 C3435T increase the risk of
leukemia: evidence from 10 case-control studies. Leuk Lymphoma.
53:1183–1187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yan Y, Liang H, Xie L, et al: Association
of MDR1 G2677T polymorphism and leukemia risk: evidence from a
meta-analysis. Tumour Biol. 35:2191–2197. 2014. View Article : Google Scholar : PubMed/NCBI
|
